INEOS Enterprises, a leading global chemical manufacturer of specialty and intermediate chemicals, announced that it has signed an agreement to acquire MBCC Group’s Admixture Business from Sika. The admixture business is a leading producer
Tags :Slider
Niederer Kraft Frey advised Diebold Self-Service Solutions, a member of the Diebold Nixdorf group, as Swiss counsel on the refinancing of certain debt and on the provision of USD 400 million in new capital for the
The Farner group, the consulting and communications agency and portfolio company of Waterland Private Equity, is expanding its marketing suite for young target groups. The company partnered with Jim&Jim to expand its agency
UBS Group successfully completed its issuance of USD 1.75 bn in aggregate principal amount of Fixed Rate/Fixed Rate Callable Senior Notes due January 2027 and USD 2.25 bn in aggregate principal amount of Fixed Rate/Fixed Rate
Advestra advised a group of finance parties as to matters of Swiss law on the refinancing of certain debt and on the provision of USD 400 million in
IMC, a global leader in market making, has entered into a definitive agreement to acquire the business of Tensor Technologies, a developer of trading software and algorithms, located in Zug, Switzerland. The transaction closed in
Niederer Kraft Frey advised Capvis, the specialist in mid-market investments and a well-known Swiss investor, on the investment into AdEx Partners. The growth strategy will be further enhanced through expansion of the service portfolio, internationalization,
Tiedemann Group, Alvarium Investments Limited and special purpose acquisition company Cartesian Growth Corporation announced that they have completed their previously announced business combination. The combined company now operates as Alvarium Tiedemann Holdings. AlTi is a
Biognosys and Bruker Corporation announced a strategic partnership, in which Bruker has made a majority-ownership investment in the company. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and
On January 5, 2023, BioVersys announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based
